goserelin acetate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 110 Diseases   158 Trials   158 Trials   1691 News 


«12345678910111213...2728»
  • ||||||||||  goserelin acetate / Generic mfg.
    GnRH Agonist Plus Medroxyprogesterone Acetate For Fertility-Sparing Treatment Of Stage IA-G1 Endometrial Cancer And Atypical Endometrial Hyperplasia (Poster area) -  Jan 18, 2024 - Abstract #ESGO2024ESGO_881;    
    Methodology Patients with AEH or ECC who were treated with GnRH agonist (Goserelin depot 3.6mg) and oral medroxyprogesterone acetate (MPA, 500mg) were included from January 2021 to January 2023 in the obstetrics and gynecology Gachon university Gil medical center, Incheon, Korea...After complete response 11 patients were treated with LNG-IUD and 5 patients have tried to conceive (Table 1). Conclusion The combination of GnRH agonist and MPA suggested promising response in AEH or ECC patients who wished to preserve their fertility.
  • ||||||||||  goserelin acetate / Generic mfg.
    Trial completion, Real-world evidence, Real-world:  Zoladex (clinicaltrials.gov) -  Jan 9, 2024   
    P=N/A,  N=1176, Completed, 
    Conclusion The combination of GnRH agonist and MPA suggested promising response in AEH or ECC patients who wished to preserve their fertility. Recruiting --> Completed
  • ||||||||||  Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Talzenna (talazoparib) / Pfizer
    Trial completion date, Trial primary completion date:  Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (clinicaltrials.gov) -  Jan 3, 2024   
    P2,  N=70, Recruiting, 
    However, differences on results between therapies for postmenopausal patients were not statistically significant. Trial completion date: Dec 2023 --> Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2027
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Biomarker, Enrollment closed, Enrollment change:  LEANORA: Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts (clinicaltrials.gov) -  Dec 20, 2023   
    P4,  N=21, Active, not recruiting, 
    Trial completion date: Dec 2023 --> Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2027 Recruiting --> Active, not recruiting | N=36 --> 21
  • ||||||||||  Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma
    Clinical study of rezvilutamide inhibiting the flare effect of GnRH agonists in the treatment of newly diagnosed metastatic prostate cancer. (Level 1, West Hall; Poster Bd # P16) -  Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_174;    
    Our previous study found that in the 3-day regimen of a new AR antagonist apalutamide (that is, GnRH agonist was given 3 days after application of apalutamide), PSA decreased by 5-10% on day 1, and PSA decreased by about 1/3 after 3 days of oral administration, which was equivalent to the inhibition of PSA synthesis by bicalutamide for 4 weeks, and no clinical symptoms were worsened...The objective of this study is to explore the efficacy and mechanism of the combined application of rezvilutamide and GnRH agonist (Goserelin Microspheres for Injection) on mHSPC to prevent flare-up...Kaplan-Meier survival analysis and Cox proportional-hazards model were used to evaluate the above indicators. Clinical trial information: ChiCTR2300076106.
  • ||||||||||  goserelin acetate / Generic mfg.
    Enrollment closed, Trial completion date:  Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia (clinicaltrials.gov) -  Dec 7, 2023   
    P=N/A,  N=60, Active, not recruiting, 
    Clinical trial information: ChiCTR2300076106. Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Aug 2024
  • ||||||||||  goserelin acetate / Generic mfg., Visanne (dienogest) / Mochida, Bayer
    Journal, IO biomarker:  Unraveling immunotherapeutic targets for endometriosis: a transcriptomic and single-cell analysis. (Pubmed Central) -  Dec 4, 2023   
    This study investigated the correlation between EMs and the immune system and identified potential immune-related biomarkers. These findings provided valuable insights for developing clinically relevant diagnostic and therapeutic strategies for EMs.
  • ||||||||||  tamoxifen / Generic mfg.
    Trial completion date, Trial primary completion date:  Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial) (clinicaltrials.gov) -  Dec 4, 2023   
    P3,  N=224, Recruiting, 
    These findings provided valuable insights for developing clinically relevant diagnostic and therapeutic strategies for EMs. Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2024
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring
    Phase classification, Monotherapy:  High-Dose Brachytherapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) -  Nov 21, 2023   
    P=N/A,  N=163, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Apr 2025 Phase classification: P1/2 --> P=N/A
  • ||||||||||  Esmya (ulipristal acetate) / ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company, Cetrotide (cetrorelix) / EMD Serono, Mifeprex (mifepristone) / Danco Laboratories
    Review, Journal:  Novel Approaches to Possible Targeted Therapies and Prophylaxis of Uterine Fibroids. (Pubmed Central) -  Nov 21, 2023   
    Three different nosological forms of the disease associated with driver mutations in the MED12, HMGA2, and FH genes should be considered when developing or prescribing drugs. For example, synthetic inhibitors and vaccines based on matrix metalloproteinases MMP11 and MMP16 are expected to be effective only for the prevention of the occurrence of MED12-dependent nodules.
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas
    Enrollment open:  ARCH: Contributions to Hypertension With Androgen Deprivation Therapy (clinicaltrials.gov) -  Nov 18, 2023   
    P4,  N=228, Recruiting, 
    For example, synthetic inhibitors and vaccines based on matrix metalloproteinases MMP11 and MMP16 are expected to be effective only for the prevention of the occurrence of MED12-dependent nodules. Not yet recruiting --> Recruiting
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Concerning Discrepancies in Estradiol Levels in Premenopausal Women Receiving Abemaciclib and Ovarian Function Suppression (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_1694;    
    As up to 91% of patients in our study may have had a false positive estradiol level erroneously suggesting inadequate OFS, monitoring of estradiol levels using the CMIA assay in patients receiving adjuvant abemaciclib in addition to OFS could lead to changes in therapy that may be unnecessary. It is recommended that the LC-MS/MS assay be used when monitoring of estradiol levels is indicated in patients receiving abemaciclib concurrently with OFS.
  • ||||||||||  Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
    A rare unilateral expression of hand-foot syndrome: a case report (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_658;    
    Preexisting hemiparesis may play a role in protecting against HFS development, suggesting the involvement of mechanical stress. Patients should be advised to avoid activities that subject the palms and soles to excessive friction.
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas
    Trial completion, Trial completion date, Trial primary completion date, HEOR, Real-world evidence, Real-world, Metastases:  Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland (clinicaltrials.gov) -  Nov 3, 2023   
    P=N/A,  N=1, Completed, 
    Safety findings support the manageable toxicity profile of RIB at the 400-mg starting dose in early breast cancer. Recruiting --> Completed | Trial completion date: Nov 2023 --> Jun 2023 | Trial primary completion date: Nov 2023 --> Jun 2023
  • ||||||||||  Epidaza (chidamide) / Chipscreen
    Trial completion, Trial completion date, Trial primary completion date:  NeoTEE: Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer (clinicaltrials.gov) -  Oct 17, 2023   
    P2,  N=30, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Jul 2022 --> Oct 2023 | Trial primary completion date: Jul 2021 --> Oct 2023
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Trial initiation date, Trial primary completion date, Real-world evidence, Real-world:  ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov) -  Oct 16, 2023   
    P3,  N=2500, Not yet recruiting, 
    Recruiting --> Completed | Trial completion date: Jul 2022 --> Oct 2023 | Trial primary completion date: Jul 2021 --> Oct 2023 Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Jun 2030 --> Jul 2028
  • ||||||||||  goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  STAMP: Strength, Aging, and Memory in Prostate Cancer (clinicaltrials.gov) -  Oct 12, 2023   
    P=N/A,  N=20, Completed, 
    Trial completion date: Sep 2023 --> Dec 2023 Active, not recruiting --> Completed | N=60 --> 20 | Trial completion date: Jul 2024 --> Apr 2023 | Trial primary completion date: Jul 2024 --> Apr 2023
  • ||||||||||  goserelin acetate / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date, Real-world evidence, Real-world:  The Benefits of Continued Use of Ovarian Function Suppression After 5 Years (clinicaltrials.gov) -  Oct 11, 2023   
    P=N/A,  N=1200, Recruiting, 
    Active, not recruiting --> Completed | N=60 --> 20 | Trial completion date: Jul 2024 --> Apr 2023 | Trial primary completion date: Jul 2024 --> Apr 2023 Active, not recruiting --> Recruiting | Trial completion date: Dec 2035 --> Sep 2028 | Trial primary completion date: Sep 2030 --> Sep 2028
  • ||||||||||  goserelin acetate / Generic mfg., exemestane / Generic mfg.
    Trial completion date, Trial primary completion date, Head-to-Head:  EVANGELINE: (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (clinicaltrials.gov) -  Oct 4, 2023   
    P2,  N=180, Recruiting, 
    Trial primary completion date: Nov 2024 --> Jun 2027 Trial completion date: Jul 2025 --> Sep 2026 | Trial primary completion date: Jan 2025 --> Feb 2026
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases:  FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (clinicaltrials.gov) -  Sep 22, 2023   
    P2,  N=116, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=194 --> 116 | Trial primary completion date: Dec 2022 --> Dec 2024